Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DAYSEE vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DAYSEE (estradiol/norethindrone acetate) is a combination hormonal contraceptive that suppresses gonadotropins (FSH and LH) via negative feedback of estrogen and progestin, thereby inhibiting ovulation. Norethindrone also increases cervical mucus viscosity and induces endometrial atrophy.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
FDA-approved: Prevention of pregnancy in women who elect to use an oral contraceptive.,Off-label: Treatment of dysmenorrhea, menstrual cycle regulation, and emergency contraception (off-label use of extended-cycle regimen).
Prevention of pregnancy (FDA-approved)
One active tablet (norgestimate 0.18 mg/ethinyl estradiol 0.025 mg) orally once daily for 21 days, followed by 7 days of placebo. Each cycle: 7 days placebo, then 21 days active.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life is approximately 24 hours (range 18-36 hours), supporting once-daily dosing for steady state within 5 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Estradiol is metabolized primarily via hydroxylation (CYP1A2, CYP3A4) and conjugation to glucuronides and sulfates. Norethindrone is metabolized via reduction and conjugation (CYP3A4).
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal 70% (metabolites), biliary/fecal 30% (parent drug and metabolites). No active drug excreted unchanged.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
99% bound to albumin (secondary to alpha-1-acid glycoprotein).
~99% bound to serum albumin and sex hormone-binding globulin.
10-15 L/kg (large distribution into tissues, including pancreas and liver).
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 75% (high; food reduces rate but not extent).
Oral: ~70% due to first-pass metabolism.
No specific dose adjustment provided. Use with caution in patients with renal impairment; monitor for fluid retention and hypertension.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in patients with impaired liver function or active liver disease. No specific dose adjustment recommended.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for postmenopausal women; no relevant use in geriatric population.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives. This risk increases with age (>35 years) and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders: venous thromboembolism, arterial thromboembolism (e.g., stroke, MI), especially in smokers ≥35 years.,Hepatic disease: discontinue if jaundice occurs; may cause cholestatic jaundice.,Hypertension: monitor blood pressure; discontinue if significant hypertension develops.,Gallbladder disease: increased risk of gallstones.,Carbohydrate/lipid metabolism: monitor in women with diabetes or hypertriglyceridemia.,Headache: evaluate if new or worsening migraine; discontinue if neurological signs.,Uterine bleeding: irregular bleeding may occur; rule out pregnancy.,Depression: monitor; discontinue if severe.,Hereditary angioedema: may exacerbate.,Ocular effects: discontinue if vision loss or proptosis.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Known or suspected pregnancy.,Current or history of thrombophlebitis or venous thromboembolic disorders.,Cerebrovascular or coronary artery disease.,Known or suspected breast carcinoma.,Carcinoma of the endometrium or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding.,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use.,Hepatic adenoma or carcinoma, or active liver disease.,Tobacco use in women ≥35 years.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food restrictions. Grapefruit juice may increase ethinyl estradiol levels; avoid large amounts. Consistent consumption of St. John's wort, certain antiepileptics (e.g., phenytoin), and rifampin can reduce contraceptive efficacy.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Daysee (progestin-only pill) has a low teratogenic risk. First trimester: no increased risk of major malformations. Second and third trimesters: no known adverse fetal effects. No association with congenital anomalies.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Compatible with breastfeeding. Progestin-only pills do not suppress lactation. Levonorgestrel is excreted in breast milk in small amounts; estimated infant dose <1% of maternal weight-adjusted dose. M/P ratio not available.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No dose adjustment is indicated; Daysee is contraindicated during pregnancy. Pregnancy should be ruled out before initiation. No pharmacokinetic changes require dose alteration.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Daysee (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive (COC) with a 91-day extended cycle regimen (84 active pills, 7 placebo). It reduces the frequency of withdrawal bleeds to 4 per year. Efficacy may be reduced if active pills are missed within the first 7 days of a new cycle. Use backup contraception if vomiting or diarrhea occurs within 3-4 hours of taking a pill.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time; missing pills increases pregnancy risk.,You will have fewer periods (about 4 per year) while on Daysee.,Use a backup method (e.g., condoms) if you miss a pill or have severe GI upset.,Do not smoke while on this medication; smoking increases risk of serious cardiovascular side effects.,Inform your doctor if you experience severe headaches, chest pain, or leg swelling.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DAYSEE vs AFIRMELLE, answered by our medical review team.
DAYSEE is a Oral Contraceptive that works by DAYSEE (estradiol/norethindrone acetate) is a combination hormonal contraceptive that suppresses gonadotropins (FSH and LH) via negative feedback of estrogen and progestin, thereby inhibiting ovulation. Norethindrone also increases cervical mucus viscosity and induces endometrial atrophy.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DAYSEE and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DAYSEE is: One active tablet (norgestimate 0.18 mg/ethinyl estradiol 0.025 mg) orally once daily for 21 days, followed by 7 days of placebo. Each cycle: 7 days placebo, then 21 days active.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DAYSEE and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DAYSEE is classified as Category C. Daysee (progestin-only pill) has a low teratogenic risk. First trimester: no increased risk of major malformations. Second and third trimesters: no known adverse fetal effects. No . AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.